Nitroglycerin (NTG), the agent most commonly used to treat acute angina pectoris, is a vasodilator whose mechanism of action remains unknown. We hypothesized that NTG might induce endothelial cells to synthesize prostacyclin (PGI2), a known vasodilator and inhibitor of platelet aggregation. Therefore, cultured human endothelial cells were incubated with NTG at various concentrations for 1-3 min. PGI2 biologic activity in the endothelial cell supernates was assayed by inhibition of platelet aggregation in vitro. The concentration of 6-keto-PGF1α, the stable hydrolysis product of PGI2, was measured by specific radioimmunoassay.
Richard I. Levin, Eric A. Jaffe, Babette B. Weksler, Karen Tack-Goldman
Usage data is cumulative from May 2024 through May 2025.
Usage | JCI | PMC |
---|---|---|
Text version | 183 | 2 |
60 | 9 | |
Scanned page | 328 | 5 |
Citation downloads | 58 | 0 |
Totals | 629 | 16 |
Total Views | 645 |
Usage information is collected from two different sources: this site (JCI) and Pubmed Central (PMC). JCI information (compiled daily) shows human readership based on methods we employ to screen out robotic usage. PMC information (aggregated monthly) is also similarly screened of robotic usage.
Various methods are used to distinguish robotic usage. For example, Google automatically scans articles to add to its search index and identifies itself as robotic; other services might not clearly identify themselves as robotic, or they are new or unknown as robotic. Because this activity can be misinterpreted as human readership, data may be re-processed periodically to reflect an improved understanding of robotic activity. Because of these factors, readers should consider usage information illustrative but subject to change.